Circulating miRNAs in diabetic retinopathy patients: Prognostic markers or pharmacological targets?

2021 ◽  
Vol 186 ◽  
pp. 114473
Author(s):  
Maria Consiglia Trotta ◽  
Carlo Gesualdo ◽  
Chiara Bianca Maria Platania ◽  
Domenico De Robertis ◽  
Mauro Giordano ◽  
...  
2018 ◽  
Vol 158 ◽  
pp. 13-26 ◽  
Author(s):  
Chiara Bianca Maria Platania ◽  
Gian Marco Leggio ◽  
Filippo Drago ◽  
Salvatore Salomone ◽  
Claudio Bucolo

2012 ◽  
Vol 18 (21) ◽  
pp. 5972-5982 ◽  
Author(s):  
Dharanija Madhavan ◽  
Manuela Zucknick ◽  
Markus Wallwiener ◽  
Katarina Cuk ◽  
Caroline Modugno ◽  
...  

2021 ◽  
Vol 41 (03) ◽  
pp. 217-224
Author(s):  
A. Garcia ◽  
Sylvie Dunoyer-Geindre ◽  
P. Fontana

AbstractMicroRNAs (miRNAs) are a class of non-coding RNAs known to repress mRNA translation and subsequent protein production. miRNAs are predicted to modulate many targets and are involved in regulating various cellular processes. Identifying their role in cell function regulation may allow circulating miRNAs to be used as diagnostic or prognostic markers of various diseases. Increasing numbers of clinical studies have shown associations between circulating miRNA levels and platelet reactivity or the recurrence of cardiovascular events. However, these studies differed regarding population selection, sample types used, miRNA quantification procedures, and platelet function assays. Furthermore, they often lacked functional validation of the miRNA identified in such studies. The latter step is essential to identifying causal relationships and understanding if and how miRNAs regulate platelet function. This review describes recent advances in translational research dedicated to identifying miRNAs' roles in platelet function regulation.


2014 ◽  
Vol 23 (12) ◽  
pp. 2632-2637 ◽  
Author(s):  
Jonas Ristau ◽  
Jürgen Staffa ◽  
Petra Schrotz-King ◽  
Biljana Gigic ◽  
Karen W. Makar ◽  
...  

2020 ◽  
Vol 52 (03) ◽  
pp. 142-148 ◽  
Author(s):  
Xin Li ◽  
Zi-Wei Yu ◽  
Ying Wang ◽  
Yu-Hong Fu ◽  
Xin-Yuan Gao

AbstractDiabetic retinopathy (DR), a serious microvascular complication of diabetes, is a leading cause of blindness in adults. The pathogenesis of DR involves a variety of tissues and complex mechanisms, such as inflammation, oxidative stress, optic neurodegeneration, and autophagy. Nowadays, microRNAs (miRNAs), a novel group of non-coding small RNAs, have been extensively studied and recognized to play a key role in the pathogenesis of DR through aforementioned pathways. Furthermore, some miRNAs have been proposed as biomarkers that may be utilized to screen for DR. Also, miRNAs are a new therapy for DR. In this review, we summarize several miRNAs and, their roles in the pathogenesis of DR. miRNAs, as potential pharmacological targets for the diabetic retinopathy, may provide new insights for the treatment of DR.


2020 ◽  
Vol 16 (3) ◽  
pp. 242-247 ◽  
Author(s):  
Abdul Hamid Al Ghamdi

Objective: This study was conducted to discuss the clinical value of published Diabetic Retinopathy Progression determinants. Methods: The data for systematic review was collected from the published studies through PubMed and Medline. These studies discussed the clinical predictors of Diabetic Retinopathy (DR) progression. The common keywords used were diabetic Retinopathy, diabetes mellitus, systolic blood pressure, hemoglobin, and albuminuria. Results: Diabetic Retinopathy is one of the common causes of irreversible visual impairment among adults. Poor glycemic control, systemic hypertension, diabetes duration, dyslipidemia, and microalbuminuria are the major risk factors for the development and progression of diabetic retinopathy. Recently, increased aortic stiffness has been identified as a prognostic marker of diabetic retinopathy and peripheral neuropathy. Conclusion: Certain groups of diabetic individuals are at higher risk to have progressive diabetic retinopathy and eventually visual impairment. Clinical determinants and predictors are considered as prognostic markers and could help physicians to develop an effective risk-based screening program for this condition.


2005 ◽  
Vol 173 (4S) ◽  
pp. 102-102 ◽  
Author(s):  
Hongjuan Zhao ◽  
Eric Bair ◽  
Robert Tibshirani ◽  
Börje Ljungberg ◽  
James D. Brooks

2004 ◽  
Vol 171 (4S) ◽  
pp. 197-197
Author(s):  
Martin G. Friedrich ◽  
Gangning Liang ◽  
Marieta I. Toma ◽  
Daniel J. Weisenberger ◽  
Jonathan C. Cheng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document